SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biolase, Inc. – ‘S-1/A’ on 2/7/24 – ‘EX-5.1’

On:  Wednesday, 2/7/24, at 6:11am ET   ·   Accession #:  1193125-24-25872   ·   File #:  333-276596

Previous ‘S-1’:  ‘S-1/A’ on 1/31/24   ·   Next:  ‘S-1/A’ on 2/9/24   ·   Latest:  ‘S-1/A’ on 3/27/24   ·   40 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/07/24  Biolase, Inc.                     S-1/A                  8:3.3M                                   Donnelley … Solutions/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Pre-Effective Amendment to Registration Statement   HTML   2.53M 
                (General Form)                                                   
 2: EX-1.3      Underwriting Agreement or Conflict Minerals Report  HTML     94K 
 3: EX-4.7      Instrument Defining the Rights of Security Holders  HTML    100K 
 4: EX-4.8      Instrument Defining the Rights of Security Holders  HTML    119K 
 5: EX-4.9      Instrument Defining the Rights of Security Holders  HTML    137K 
 6: EX-5.1      Opinion of Counsel re: Legality                     HTML     23K 
 7: EX-10.25    Material Contract                                   HTML    196K 
 8: EX-FILING FEES  Filing Fees                                     HTML     61K 


‘EX-5.1’   —   Opinion of Counsel re: Legality


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-5.1  

Exhibit 5.1

 

LOGO

1271 Avenue of the Americas | New York, NY 10020

blankrome.com

February 7, 2024

BIOLASE, Inc.

27042 Towne Centre Drive, Suite 270

Lake Forest, California 92610

Re: BIOLASE, Inc. Registration Statement on Form S-1 (File No. 333-276596)

Dear Ladies and Gentlemen:

We have acted as U.S. securities counsel to BIOLASE, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), of a Registration Statement on Form S-1 (File No. 333-276596) (as amended through the date hereof, the “Registration Statement”) relating to the registration by the Company of (i) up to $7,500,000 of units (“Units”), with each Unit consisting of (A) one share (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (B) one Class A warrant (each, a “Class A Common Warrant” and collectively, the “Class A Common Warrants”) to purchase one share of Common Stock, each such Class A Common Warrant being exercisable from time to time for one share of Common Stock (the “Class A Common Warrant Shares”), and (C) one Class B warrant (each, a “Class B Common Warrant” and collectively, the “Class B Common Warrants” and collectively with the Class A Common Warrants, the “Common Warrants”) to purchase one share of Common Stock, each such Class B Common Warrant being exercisable from time to time for one share of Common Stock (the “Class B Common Warrant Shares” and collectively with the Class A Common Warrant Shares, the “Common Warrant Shares”); (ii) up to $7,500,000 of pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of (A) one pre-funded warrant (each, a “Pre-Funded Warrant” and collectively, the “Pre-Funded Warrants”), each such Pre-Funded Warrant being exercisable from time to time for one share of Common Stock (the “Pre-Funded Warrant Shares”), (B) one Class A Common Warrant and (C) one Class B Common Warrant, (iii) the Pre-Funded Warrant Shares, and (iv) the Common Warrant Shares. The Units, Shares, Common Warrants, Common Warrant Shares, Pre-Funded Units, Pre-Funded Warrants and Pre-Funded Warrant Shares are collectively referred to herein as the “Securities”. The Securities will be sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) between the Company and certain investors identified on the signature pages thereto (collectively, the “Investors”). As noted in the Registration Statement, for each Pre-Funded Unit sold, the number of Units sold will be decreased on a one-for-one basis. The Common Warrants and the Pre-Funded are being issued pursuant to the terms of that certain warrant agency agreement (the “Warrant Agency Agreement”) to be entered into by and among the Company, Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (together with Computershare, the “Warrant Agent”), the form of which Warrant Agency Agreement has been, or will be, filed as Exhibit 4.9 to the Registration Statement.

In our capacity as counsel to the Company, we have examined the original or certified copies of such records of the Company and such agreements, certificates of public officials, certificates of officers or representatives of the Company and others, and such other documents as we deem relevant and necessary as a basis for the opinions hereinafter expressed, including, but not limited to, the Company’s restated certificate of incorporation, as amended (the “Certificate of Incorporation”), the Common Warrants, the Pre-Funded Warrants and the Warrant Agency Agreement. In rendering this opinion, we have assumed, without inquiry, (i) the authenticity of all documents submitted to us as originals; (ii) the conformity to the original documents of all documents submitted to us as facsimile, electronic, certified or photostatic copies, and the authenticity of the originals of such copies; (iii) the legal capacity of all natural persons and the genuineness of all signatures on all documents submitted to us; and (iv) that the books and records of the Company are maintained in accordance with proper corporate procedures. As to various questions of fact material to such opinions, we have relied upon statements or certificates of officials and representatives of the Company and others.

Blank Rome LLP | blankrome.com


LOGO

BIOLASE, Inc.

February 7, 2024

Page 2

Based on the foregoing, and subject to the qualifications, exceptions and assumptions stated herein, we are of the opinion that:

 

  1.

When the Units are issued and delivered and paid for (i) in accordance with the terms of the Purchase Agreement, and (ii) in accordance with and in the manner described in the Registration Statement, the Units will be legally binding obligations of the Company enforceable in accordance with their terms.

 

  2.

When the Pre-Funded Units are issued and delivered and paid for (i) in accordance with the terms of the Purchase Agreement, and (ii) in accordance with and in the manner described in the Registration Statement, the Pre-Funded Units will be legally binding obligations of the Company enforceable in accordance with their terms.

 

  3.

The Shares have been duly authorized for issuance and, when issued, delivered and paid for as contemplated in the Purchase Agreement and the Registration Statement, the Shares will be validly issued, fully paid and non-assessable.

 

  4.

When the Common Warrants are issued, delivered and paid for, as contemplated in the Purchase Agreement and the Registration Statement, the Common Warrants will constitute valid and binding obligations of the Company.

 

  5.

When the Pre-Funded Warrants are issued, delivered and paid for, as contemplated in the Purchase Agreement and the Registration Statement, the Pre-Funded Warrants will constitute valid and binding obligations of the Company.

 

  6.

The Common Warrant Shares have been duly authorized for issuance and, when issued and delivered against payment therefor upon the exercise of the Common Warrants in accordance with the terms therein, the Common Warrant Shares will be validly issued, fully paid and non-assessable.

 

  7.

The Pre-Funded Warrant Shares have been duly authorized for issuance and, when issued and delivered against payment therefor upon the exercise of the Pre-Funded Warrants in accordance with the terms therein, the Pre-Funded Warrant Shares will be validly issued, fully paid and non-assessable.

In addition to the assumptions, comments, qualifications, limitations and exceptions set forth above, the opinions set forth herein are further limited by, subject to and based upon the following:

 

  1.

We are opining solely on all applicable statutory provisions of Delaware corporate law, including the rules and regulations underlying those provisions, all applicable provisions of the Delaware Constitution and all applicable judicial and regulatory determinations. This opinion is limited (i) to the laws of the State of Delaware as in effect on the date hereof and (ii) as to the Common Warrants and the Pre-Funded Warrants constituting valid and binding obligations of the Company, the applicable laws of the State of New York in effect on the date hereof that, in our experience, are normally applicable to transactions of the type contemplated by the Common Warrants and the Pre-Funded Warrants. We express no opinion with respect to the laws of any other jurisdiction.

Blank Rome LLP | blankrome.com


LOGO

BIOLASE, Inc.

February 7, 2024

Page 3

 

  2.

Our opinions are subject to, and may be limited by, (i) applicable bankruptcy, reorganization, insolvency, conservatorship, moratorium, fraudulent conveyance, fraudulent transfer, and similar laws and court decisions affecting the rights and remedies of creditors and secured parties generally, and (ii) general principles of equity (including, without limitation, concepts of materiality, reasonableness, impossibility of performance, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.

 

  3.

Our opinions are subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request is brought.

 

  4.

We express no opinion as to any provision of the Common Warrants and the Pre-Funded Warrants that: (i) provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (ii) relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (iii) restricts non-written modifications and waivers, (iv) provides for the payment of legal and other professional fees where such payment is contrary to law or public policy, (v) relates to exclusivity, election or accumulation of rights or remedies, (vi) authorizes or validates conclusive or discretionary determinations, or (vii) provides that provisions of the Common Warrants and the Pre-Funded Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable.

 

  5.

We express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New York law or jurisdiction provided for in the Common Warrants and Pre-Funded Warrants.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also hereby consent to the use of our name as your counsel under “Legal Matters” in the Prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby concede that we come within the categories of persons whose consent is required by the Securities Act or the General Rules and Regulations promulgated thereunder. This opinion is strictly limited to the matters stated herein and no other or more extensive opinion is intended, implied or to be inferred beyond the matters expressly stated herein. This opinion letter is not a guaranty nor may one be inferred or implied.

 

Very truly yours,

/s/ BLANK ROME

BLANK ROME LLP

Blank Rome LLP | blankrome.com


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1/A’ Filing    Date    Other Filings
Filed on:2/7/248-K
 List all Filings 


3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/24  Biolase, Inc.                     POS AM                 1:1.1M                                   Donnelley … Solutions/FA
 4/11/24  Biolase, Inc.                     POS AM                 3:1.1M                                   Donnelley … Solutions/FA
 2/09/24  Biolase, Inc.                     S-1/A                  4:3M                                     Donnelley … Solutions/FA


37 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/31/24  Biolase, Inc.                     S-1/A                  9:3.2M                                   Donnelley … Solutions/FA
 1/19/24  Biolase, Inc.                     S-1                    3:2.6M                                   Donnelley … Solutions/FA
12/08/23  Biolase, Inc.                     8-K:1,3,8,912/06/23   16:767K                                   Donnelley … Solutions/FA
 9/18/23  Biolase, Inc.                     8-K:1,3,5,8 9/13/23   16:887K                                   Donnelley … Solutions/FA
 8/30/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 6/23/23  Biolase, Inc.                     8-K:4,9     6/21/23   11:147K                                   Donnelley … Solutions/FA
 6/06/23  Biolase, Inc.                     8-K:3,5,8,9 6/05/23   12:225K                                   Donnelley … Solutions/FA
 5/26/23  Biolase, Inc.                     8-K:1,3,5,8 5/24/23   16:890K                                   Donnelley … Solutions/FA
 3/28/23  Biolase, Inc.                     10-K       12/31/22   90:19M                                    Donnelley … Solutions/FA
 1/05/23  Biolase, Inc.                     8-K:1,9    12/30/22   11:1.3M                                   Donnelley … Solutions/FA
11/10/22  Biolase, Inc.                     10-Q        9/30/22   83:14M                                    Donnelley … Solutions/FA
 6/08/22  Biolase, Inc.                     8-K:3,5,7,9 6/08/22   12:10M                                    Donnelley … Solutions/FA
 5/02/22  Biolase, Inc.                     8-K:5,9     4/28/22   11:180K                                   Donnelley … Solutions/FA
 3/03/22  Biolase, Inc.                     8-K:3,5,7,9 3/01/22   13:359K                                   Donnelley … Solutions/FA
 3/03/22  Biolase, Inc.                     8-A12G                 2:46K                                    Donnelley … Solutions/FA
11/10/21  Biolase, Inc.                     10-Q        9/30/21   84:13M                                    Donnelley … Solutions/FA
 4/19/21  Biolase, Inc.                     DEF 14A     5/26/21    1:1.2M                                   Donnelley … Solutions/FA
 6/01/20  Biolase, Inc.                     8-K:5,9     5/28/20    2:26K                                    Donnelley … Solutions/FA
 5/08/20  Biolase, Inc.                     10-Q        3/31/20   86:8.5M                                   ActiveDisclosure/FA
 4/23/20  Biolase, Inc.                     DEF 14A     5/13/20    1:1.5M                                   ActiveDisclosure/FA
 3/30/20  Biolase, Inc.                     10-K       12/31/19   90:24M                                    ActiveDisclosure/FA
 9/05/19  Biolase, Inc.                     S-1         9/04/19    3:929K                                   Donnelley … Solutions/FA
 4/10/19  Biolase, Inc.                     DEF 14A     5/15/19    1:971K                                   Donnelley … Solutions/FA
11/14/18  Biolase, Inc.                     10-Q        9/30/18   81:11M                                    ActiveDisclosure/FA
 8/24/18  Biolase, Inc.                     DEF 14A     9/21/18    1:1.6M                                   Donnelley … Solutions/FA
 5/11/18  Biolase, Inc.                     8-K:5,9     5/10/18    2:26K                                    Donnelley … Solutions/FA
 4/05/18  Biolase, Inc.                     DEF 14A     5/09/18    1:717K                                   Donnelley … Solutions/FA
10/03/17  Biolase, Inc.                     8-K:5,7,8,9 9/30/17    4:90K                                    Donnelley Fi… Express/FA
 7/21/17  Biolase, Inc.                     S-3                    4:281K                                   ActiveDisclosure/FA
 4/07/16  Biolase, Inc.                     DEF 14A     5/06/16    1:1M                                     Donnelley … Solutions/FA
11/06/15  Biolase, Inc.                     10-Q        9/30/15   68:7.2M                                   ActiveDisclosure/FA
11/04/14  Biolase, Inc.                     8-A12B/A               3:38K                                    Donnelley … Solutions/FA
 5/16/12  Biolase, Inc.                     8-K:5,7,9   5/10/12    3:44K                                    Donnelley Fi… Express/FA
12/23/05  Biolase, Inc.                     S-1/A                  6:2.3M                                   Donnelley … Solutions/FA
11/09/05  Biolase, Inc.                     10-Q        9/30/05    9:771K                                   Donnelley … Solutions/FA
 7/19/05  Biolase, Inc.                     10-K       12/31/04   17:2.2M                                   Donnelley … Solutions/FA
 6/03/02  Biolase, Inc.                     S-3                    6:225K                                   Donnelley R R & S… 11/FA
Top
Filing Submission 0001193125-24-025872   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 11:52:06.3am ET